TNGX · XBRL financial data

Tango Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TNGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	7,656	37,042	24,860	36,527	42,069	62,384
Research and development	49,991	77,636	105,906	115,198	143,918	132,165
General and administrative	9,865	17,596	30,025	35,502	43,746	41,508
Total operating expenses	59,856	95,232	135,931	150,700	187,664	173,673
Operating income (loss)	(52,200)	(58,190)	(111,071)	(114,173)	(145,595)	(111,289)
Other income (expense)	120	(248)	1,493	5,944	7,611	4,069
Income tax expense (benefit)	0	292	54	134	208	4
Net income (loss)	(51,972)	(58,235)	(108,176)	(101,744)	(130,302)	(101,594)
Earnings per share, basic USD per share	—	(0.94)	(1.23)	(1.08)	(1.19)	(0.87)
Earnings per share, diluted USD per share	—	(0.94)	(1.23)	(1.08)	(1.19)	(0.87)
Weighted average shares, basic thousands of shares	—	62,108	87,820	94,572	109,227	116,166
Weighted average shares, diluted thousands of shares	—	62,108	87,820	94,572	109,227	116,166

† Share count changed about 4x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TNGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,314	142,745	59,968	66,385	69,530	112,279
Marketable securities	161,939	342,510	306,165	270,500	188,387	230,859
Accounts receivable	2,000	2,000	2,000	—	—	—
Prepaid and other current assets	1,312	4,516	6,572	8,797	8,426	10,190
Total current assets	1,498	492,338	375,272	346,538	266,343	353,756
Property and equipment, net	3,823	4,832	10,884	9,908	8,102	6,868
Right-of-use asset	7,480	1,254	46,886	43,508	39,476	35,624
Total assets	168,313	500,155	436,470	402,567	316,492	398,690
Accounts payable	1,841	3,226	4,453	2,785	1,601	1,182
Accrued liabilities	75	—	—	—	—	—
Total current liabilities	114	40,690	55,545	45,938	38,170	21,679
Lease liability, non-current	6,925	—	39,361	36,838	34,039	30,832
Total liabilities	5,951	155,408	186,994	149,459	116,975	52,511
Accumulated deficit	(123)	(161,336)	(269,512)	(371,256)	(501,558)	(603,152)
Total stockholders' equity	5,000	344,747	249,476	253,108	199,517	346,179
Total liabilities and equity	168,313	500,155	436,470	402,567	316,492	398,690
Common shares outstanding (cover page) thousands of shares	21,377	87,707	88,203	106,718	108,108	142,689

† Share count changed about 4x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TNGX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(51,972)	(58,235)	(108,176)	(101,744)	(130,302)	(101,594)
Stock-based compensation	1,764	7,833	14,230	19,079	28,897	26,430
Net cash from operating activities	70,074	(59,527)	(109,080)	(117,982)	(131,501)	(138,886)
Purchases of property and equipment	1,106	1,837	7,692	1,526	754	1,048
Net cash from investing activities	(145,466)	(183,434)	26,399	41,426	86,126	(40,865)
Net cash from financing activities	80,884	357,325	1,615	82,406	47,664	222,500
Net change in cash	5,492	114,364	(81,066)	5,850	2,289	42,749

† Share count changed about 4x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Tango Therapeutics	345,558	0	(38,866)*	168.6M	26.1 quarters	Q2 FY26 10-QJun 30, 2026
Elite Pharmaceuticals	39,416	32,355	10,070	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	57,934	121,469	not reported	462.7M	—	Q3 FY26 10-QSep 30, 2026
Opko Health	384,036	65,414	(36,315)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Savara	41,800	not reported	(29,747)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	59,622	116,520	2,642*	75.0M	—	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Evolus	41,700	77,952	(1,933)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.